Barrington analyst Kevin Steinke lowered the firm’s price target on Cross Country Healthcare to $26 from $29 and keeps an Outperform rating on the shares post the Q3 report. The company’s Q4 outlook reflects challenging near-term market conditions, the analyst tells investors in a research note. However, the firm says Cross Country is experiencing strong new business momentum for Intellify, its proprietary vendor management system that was launched in the second half of 2022.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CCRN:
- Cross Country Healthcare downgraded to Hold from Buy at Jefferies
- AMN Healthcare downgraded to Hold from Buy at Jefferies
- Cross Country Healthcare price target lowered to $24 from $31 at Benchmark
- Cross Country Healthcare sees Q4 adjusted EPS 25c-35c, consensus 45c
- Cross Country Healthcare reports Q3 adjusted EPS 39c, consensus 41c
